tetano
Editor, Senior Moderator
Heart Lung Circ
. 2022 Apr 6;S1443-9506(22)00105-6.
doi: 10.1016/j.hlc.2022.03.003. Online ahead of print.
Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination: A Pragmatic Narrative Review to Guide Clinical Practice
David J Holland[SUP] 1 [/SUP], Penni L Blazak[SUP] 2 [/SUP], Joshua Martin[SUP] 2 [/SUP], Jennifer Broom[SUP] 3 [/SUP], Rohan S Poulter[SUP] 2 [/SUP], Tony Stanton[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is likely to remain endemic globally despite widespread vaccination. There is increasing concern for myocardial involvement and ensuing cardiac complications due to COVID-19, however, the available evidence suggests these risks are low. Pandemic publishing has resulted in rapid manuscript availability though pre-print servers. Subsequent article retractions, a lack of standardised definitions, over-reliance on isolated troponin elevation and the heterogeneity of studied patient groups (i.e. severe vs. symptomatic vs all infections) resulted in early concern for high rates of myocarditis in patients with and recovering from COVID-19. The estimated incidence of myocarditis in COVID-19 infection is 11 cases per 100,000 infections compared with an estimated 2.7 cases per 100,000 persons following mRNA vaccination. For substantiated cases, the clinical course of myocarditis related to COVID-19 or mRNA vaccination appears mild and self-limiting, with reports of severe/fulminant myocarditis being rare. There is limited data available on the management of myocarditis in these settings. Clinical guidance for appropriate use of cardiac investigations and monitoring in COVID-19 is needed for effective risk stratification and efficient use of cardiac resources in Australia. An amalgamation of national and international position statements and guidelines is helpful for guiding clinical practice. This paper reviews the current available evidence and guidelines and provides a summary of the risks and potential use of cardiac investigations and monitoring for patients with COVID-19.
Keywords: Biomarker; COVID-19; Cardiac magnetic resonance imaging; Coronavirus; Echocardiography; Myocarditis; Pericarditis; SARS-CoV-2; Troponin; Vaccination; mRNA.
. 2022 Apr 6;S1443-9506(22)00105-6.
doi: 10.1016/j.hlc.2022.03.003. Online ahead of print.
Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination: A Pragmatic Narrative Review to Guide Clinical Practice
David J Holland[SUP] 1 [/SUP], Penni L Blazak[SUP] 2 [/SUP], Joshua Martin[SUP] 2 [/SUP], Jennifer Broom[SUP] 3 [/SUP], Rohan S Poulter[SUP] 2 [/SUP], Tony Stanton[SUP] 4 [/SUP]
Affiliations
- PMID: 35398005
- DOI: 10.1016/j.hlc.2022.03.003
Abstract
Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is likely to remain endemic globally despite widespread vaccination. There is increasing concern for myocardial involvement and ensuing cardiac complications due to COVID-19, however, the available evidence suggests these risks are low. Pandemic publishing has resulted in rapid manuscript availability though pre-print servers. Subsequent article retractions, a lack of standardised definitions, over-reliance on isolated troponin elevation and the heterogeneity of studied patient groups (i.e. severe vs. symptomatic vs all infections) resulted in early concern for high rates of myocarditis in patients with and recovering from COVID-19. The estimated incidence of myocarditis in COVID-19 infection is 11 cases per 100,000 infections compared with an estimated 2.7 cases per 100,000 persons following mRNA vaccination. For substantiated cases, the clinical course of myocarditis related to COVID-19 or mRNA vaccination appears mild and self-limiting, with reports of severe/fulminant myocarditis being rare. There is limited data available on the management of myocarditis in these settings. Clinical guidance for appropriate use of cardiac investigations and monitoring in COVID-19 is needed for effective risk stratification and efficient use of cardiac resources in Australia. An amalgamation of national and international position statements and guidelines is helpful for guiding clinical practice. This paper reviews the current available evidence and guidelines and provides a summary of the risks and potential use of cardiac investigations and monitoring for patients with COVID-19.
Keywords: Biomarker; COVID-19; Cardiac magnetic resonance imaging; Coronavirus; Echocardiography; Myocarditis; Pericarditis; SARS-CoV-2; Troponin; Vaccination; mRNA.